• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

How to Manage Risk in Biotech Stocks

T2 Biosystems' recent run-up on a positive event provides an important lesson for biotech investors.
By BRET JENSEN
Jun 03, 2018 | 10:00 AM EDT
Stocks quotes in this article: TTOO

I was out having a coffee a few hours before the market opened Tuesday at my favorite coffee place here in downtown Miami (not Starbucks) with a friend. Karl is an ex-Brooklynite who now splits time between Miami and London. We were engaged in our favorite topic. The ascendancy of the Evil Empire (AKA, my beloved NY Yankees) and the fate of his miserable Mets, who look more like a M.A.S.H. unit than a baseball team for the third year in a row.

We were in the middle of a hypothetical trade scenario that made sense for both teams around the Mets' ace pitcher Jacob deGrom, when I got an email notification that T2 Biosystems (TTOO) was trading up 10% in pre-market as the FDA approved their new bacterial panel. Karl was quite happy with the news as he had taken my advice and loaded up on the shares in the mid-$4s several months ago and now the stock was trading near $10 on the news.

My first reaction was to ask if he had sold covered calls on a good portion of his holdings as I suggested late the week before. He looked at me quizzically and perplexedly inquired if this wasn't great news for the stock. I stated that it was fantastic news for the company as they now possessed a product that could reduce the time to test for Sepsis into hours from the current standard process. This will cut drastically the amount of time needed to detect and treat this deadly bacterium that kills tens of thousands every year in hospitals throughout the United States.

Source: T2 Biosystems

It was also great news for long-term shareholders and probably increased T2 Biosystems desirability as a potential buyout target significantly as well. However, the shares had also run up some 50% in the three weeks leading into this approval. Historically, this in most cases means after the initial euphoria of the positive news wears off, the stock will see some "buy the rumor, sell the news" trading behavior usually that same trading day.

In addition, small developmental firms like T2 Biosystems often use these sorts of run-ups on positive events to raise additional capital via secondary offerings. Indeed, that is exactly what happened with TTOO Tuesday. The stock gave way to its initial bout of enthusiasm early in trading and ended up down 9% on the day. The company then announced a secondary offering right after the market closed, knocking the shares down another 7% percent in after-hours trading.

I ran into Karl in our building's gym several hours later. He was beaming ear to ear. I asked if he had time to sell out-of-the-money call options against his holdings at market open. "Yep, I got some nice options premiums against my stock as well. Happy hour is on me." My reply was "Let's make it Capital Grille."

The lesson of this little story is that this sort of option strategy should be every investors' "tool box" that invests in biotech given the high-beta nature of the sector. This is a great way to mitigate some risk and the option premiums are usually more than solid. Or as Real Money's Jim Cramer is fond of saying, "Bulls make money. Bears make money. Pigs get slaughtered."

(This column originally appeared May 30 on Real Money Pro, our premium site for active traders and Wall Street professionals. Click here to get great columns like this each day.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long TTOO.

TAGS: Investing | U.S. Equity | Regulation | Markets | Healthcare | How-to | Options | Risk Management | Stocks

More from Healthcare

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:07 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/20/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login